Diminished Prognostic Value of Interim PET in Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus AVD: A Retrospective Analysis
Hematology Reports · 31.07.2026 · 18 (4) · 53
DOI: 10.3390/hematolrep18040053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 31.07.2026. Verfasst von Kareem Latif und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Loma Linda University School of Medicine, Loma Linda University Medical Center, Loma Linda, CA 92350, USA. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Interim PET after two cycles (PET2) has historically guided risk-adapted therapy in Hodgkin lymphoma (HL). Its value with frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV + AVD) is uncertain, as BV + AVD improves progression-free survival and may reduce the prognostic relevance of early metabolic response. Our aim was to assess whether PET2 retains prognostic utility in HL patients treated with BV + AVD.
Methods
We retrospectively reviewed 55 newly diagnosed classical HL patients treated with frontline BV + AVD. The primary endpoint was PET2 performance for predicting EOT PET positivity. Sensitivity, specificity, predictive values, and likelihood ratios were calculated with 95% confidence intervals.
Results
Median age was 22 years (range 11–77), 49% were male, and 73% had stage III–IV disease. PET2 was negative in 51 patients (92.7%) and positive in 4 (7.3%). EOT PET was negative in 48 (87.3%) and positive in 7 (12.7%). Of seven EOT PET-positive patients, three were PET2-positive and four PET2-negative. Of 48 EOT PET-negative patients, 47 were PET2-negative and 1 PET2-positive. PET2 sensitivity was 42.9%, specificity 97.9%, positive predictive value 75.0%, and negative predictive value 92.2%. Positive likelihood ratio was 20.6; negative likelihood ratio was 0.58.
Conclusions
In HL patients treated with BV + AVD, most achieve PET2 negativity, limiting interim PET discrimination. Negative PET2 adds little reassurance beyond the high baseline success rate, while positive PET2 is uncommon and identifies only a subset of eventual treatment failures. These findings question the routine use of PET2 to guide therapy in the BV + AVD era.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Loma Linda University School of Medicine, Loma Linda University Medical Center, Loma Linda, CA 92350, USA.
- School of Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
- Department of Medicine, Division of Hematology/Oncology, University of California Irvine, Irvine, CA 92868, USA.
- Department of Medicine, Division of Transplant, Cellular Therapy, and Hematological Malignancies, Loma Linda University School of Medicine, Loma Linda University Medical Center, Loma Linda, CA 92350, USA.
ORCID-Profile: Kareem Latif, Faisal Ansari
Zitieren
APA
Latif, K., Courtad, I., Stuart, A., Ansari, F., Samaeekia, R., & Akhtari, M. (2026). Diminished Prognostic Value of Interim PET in Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus AVD: A Retrospective Analysis. Hematology Reports, 18(4), 53. https://doi.org/10.3390/hematolrep18040053
Vancouver
Latif K, Courtad I, Stuart A, Ansari F, Samaeekia R, Akhtari M. Diminished Prognostic Value of Interim PET in Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus AVD: A Retrospective Analysis. Hematology Reports. 2026;18(4):53. doi:10.3390/hematolrep18040053
BibTeX
@article{Latif2026,
author = {Latif, Kareem and Courtad, Isaiah and Stuart, Avery and Ansari, Faisal and Samaeekia, Ravand and Akhtari, Mojtaba},
title = {Diminished Prognostic Value of Interim PET in Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus AVD: A Retrospective Analysis},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {4},
pages = {53},
doi = {10.3390/hematolrep18040053}
}
EUVIMED